Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IN8BIO, INC.INAB · Entity 7941 | Director | December 22, 2025 | December 23, 2025 |
| NexImmune, Inc.NEXI · Entity 89921 | Director | November 21, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IN8BIO, INC.
Report date December 22, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,514 |
Reported balance
After 2025-12-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-22 · Grant · Acquired 36,232 · Balance 49,514 F1: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
NexImmune, Inc.
Report date November 21, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-11-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-11-21 · Sale · Disposed 3,833 · Balance 3,992 F1: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.39 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price. Row 2 · 2023-11-22 · Sale · Disposed 3,992 · Balance 0 F2: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.05 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.39 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price.
F2: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.05 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2025 Filed Dec 23, 2025 18:20 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantCommon Stock | 36,232 | $1.38 | $50,000.16 |
DisclosureSEC source: 0001643070-25-000005 · form4-12232025_061205.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,514 F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. Read SEC document |
| May 08, 2025 Filed May 12, 2025 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 63,150 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001415889-25-012649 · form4-05122025_040507.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,150 Underlying: Common Stock · 63,150 shares Expires 2035-05-08 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 30, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Exercise / conversionSeries B Warrants (right to buy) · Derivative | 11,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 8 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2025-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 30, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Exercise / conversionSeries A Warrants (right to buy) · Derivative | 102,459 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 5 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,459 shares Expires 2025-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 30, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Exercise / conversionCommon Stock | 11,000 | $0.18 | $2,028.40 |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · nonDerivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Exercise / conversionCommon Stock | 102,459 | $0.18 | $18,893.44 |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 91,459 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 9 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,459 Underlying: Common Stock · 91,459 shares Expires 2028-12-13 F5 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F4 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 11,000 | Not disclosed Strike: $0.18 | Not disclosed |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 7 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2025-05-02 F4 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. F4 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Disposition to issuerSeries B Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 6 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,459 shares Expires 2028-12-13 F4 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. F3 · price: The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F4 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries A Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $0.18 | Not disclosed |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 4 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,459 Underlying: Common Stock · 102,459 shares Expires 2025-05-02 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 7, 2025 20:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Disposition to issuerSeries A Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,459 shares Expires 2025-10-04 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. F3 · price: The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 93,242 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-030060 · form4-12232024_041211.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,242 Underlying: Common Stock · 93,242 shares Expires 2034-12-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries C Warrants (right to buy) · Derivative | 126,582 | Not disclosed Strike: $0.27 | Not disclosed |
DisclosureSEC source: 0001415889-24-024868 · form4-10082024_041006.xml · derivative · entry 4 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,582 Underlying: Common Stock · 126,582 shares Expires 2027-10-04 F1 · price: The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries A Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001415889-24-024868 · form4-10082024_041006.xml · derivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,459 Underlying: Common Stock · 102,459 shares Expires 2025-10-04 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. F4 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | Disposition to issuerSeries A Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001415889-24-024868 · form4-10082024_041006.xml · derivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,459 shares Expires 2025-06-13 F2 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. F2 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. F4 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F3 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantCommon Stock | 126,582 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-024868 · form4-10082024_041006.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,030 F1 · price: The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 17:00 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 33,650 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016964 · form4-06142024_050603.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,650 Underlying: Common Stock · 33,650 shares Expires 2034-06-12 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 08:25 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001209191-23-058719 · doc4.xml · derivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,459 Underlying: Common Stock · 102,459 shares Expires 2028-12-13 F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 08:25 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries A Warrants (right to buy) · Derivative | 102,459 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-058719 · doc4.xml · derivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,459 Underlying: Common Stock · 102,459 shares Expires 2025-06-13 F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 08:25 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantCommon Stock | 102,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-058719 · doc4.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,448 F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. Read SEC document |
| November 22, 2023 Filed Nov 22, 2023 17:18 UTC | NexImmune, Inc. NEXI · Entity 89921 | SaleCommon Stock | 3,992 | $1.94 | $7,758.05 |
DisclosureSEC source: 0001209191-23-056514 · doc4.xml · nonDerivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.05 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 17:18 UTC | NexImmune, Inc. NEXI · Entity 89921 | SaleCommon Stock | 3,833 | $2.16 | $8,287.33 |
DisclosureSEC source: 0001209191-23-056514 · doc4.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,992 F1 · price: The price reflects the average selling price of the common stock sold. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.39 per common stock. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of common stock sold at each price. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:17 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 44,983 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0000950170-23-032247 · ownership.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,983 Underlying: Common Stock · 44,983 shares Expires 2033-07-04 Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 19:42 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-038119 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 3,856 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 8 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,856 Underlying: Common Stock · 3,856 shares Expires 2029-03-18 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. F4 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 3,856 | Not disclosed Strike: $4.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 7 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,856 shares Expires 2029-03-18 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. F4 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Mr. Roemer has exercised his right to purchase 42,389 shares subject to the original option. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 23,122 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 6 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,122 Underlying: Common Stock · 23,122 shares Expires 2030-03-04 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 23,122 | Not disclosed Strike: $5.17 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 5 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,122 shares Expires 2030-03-04 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 9,556 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 4 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,556 Underlying: Common Stock · 9,556 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 9,556 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,556 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 61,678 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:43 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 61,678 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001209191-23-023689 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Roemer's continued service on such vesting date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 16:08 UTC | IN8BIO, INC. INAB · Entity 7941 | PurchaseCommon Stock | 26,315 | $1.90 | $49,998.50 |
DisclosureSEC source: 0001209191-22-046600 · doc4.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,989 Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 16:59 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (Right to Buy) · Derivative | 61,678 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-22-037013 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 Read SEC document |
| June 01, 2022 Filed Jun 14, 2022 19:02 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-22-036802 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 1, 2022 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 01, 2022 Filed Sep 23, 2022 17:08 UTC Amendment | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-22-051163 · doc4a.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2032-06-01 F1 · shares: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 1, 2022 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. F1 · derivative.underlying_shares: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. F1 · balance_after: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionStock Option (right to buy) · Derivative | 42,389 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · derivative · entry 6 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856 Underlying: Common Stock · 42,389 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 33.33% of the shares vested on March 19, 2020; the remainder vests monthly on the 19th of every month until March 19, 2022. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionStock Option (right to buy) · Derivative | 12,634 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · derivative · entry 5 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,634 shares Expires 2028-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionStock Option (right to buy) · Derivative | 12,634 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · derivative · entry 4 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,634 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionCommon Stock | 42,389 | $4.31 | $182,696.59 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · nonDerivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionCommon Stock | 12,634 | $2.58 | $32,595.72 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · nonDerivative · entry 2 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 17:00 UTC | NexImmune, Inc. NEXI · Entity 89921 | Exercise / conversionCommon Stock | 12,634 | $2.42 | $30,574.28 |
DisclosureSEC source: 0001209191-21-070944 · doc4.xml · nonDerivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 16:39 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 86,258 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-066459 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,258 Underlying: Common Stock · 86,258 shares Expires 2031-11-19 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest on the last day of each calendar quarter commencing on September 30, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:35 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049163 · doc4.xml · derivative · entry 1 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-07-29 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on August 29, 2021 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionConvertible Promissory Note · Derivative | Not disclosed | Not disclosed | $104,570.00 |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · derivative · entry 8 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,268 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F2 · price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F2 · derivative.exercise_date: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A3 Preferred Stock · Derivative | 26,590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · derivative · entry 7 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F3 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A2 Preferred Stock · Derivative | 4,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · derivative · entry 6 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F3 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A Preferred Stock · Derivative | 85,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · derivative · entry 5 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F3 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 12,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · nonDerivative · entry 4 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:26 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 26,590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012364 · doc4.xml · nonDerivative · entry 3 Roemer Alan S. · CIK 0001643070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.